

FORM PTO-1449	SERIAL NO. 10/047,710	CASE NO. 11170/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE January 15 <sup>th</sup> , 2002	GROUP ART UNIT
(use several sheets if necessary)	APPLICANT(S): Das Gupta et al.	

## REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
my	A1 ✓	Zaborina, O. et al., "P2Z independent and P2Z receptor mediated macrophage killing by <i>P. aeruginosa</i> isolated from cystic fibrosis patients", Infect. Immun. 67: 5231-5242 (1999).
	A2 ✓	Melnikov, A. et al., "Clinical and environmental isolates of <i>Burkholderia cepacia</i> exhibit differential cytotoxicity towards macrophages and mast cells", Mol. Microbiol. 36: 1481-1493 (2000).
	A3 ✓	Punj, V. et al., "Phagocytic cell killing mediated by secreted cytotoxic factors of <i>Vibrio cholerae</i> ", Infect. Immun. 68: 4930-4937 (2000).
	A4 ✓	Zaborina, O. et al., "Secreted products of a nonmucoid <i>Pseudomonas aeruginosa</i> strain induce two modes of macrophage killing: external ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis", Microbiology 146: 2521-2530 (2000).
	A5 ✓	Kirn, David H. et al., "Replication-selective microbiological agents fighting cancer with targeted germ warfare", The Journal of Clinical Investigation, vol. 105, No. 7, 837-839 (2000).
	A6 ✓	Sznol, Mario et al., "Use of Preferentially Replicating Bacteria for the Treatment of Cancer", The Journal of Clinical Investigation, vol. 105, No. 8, 1027-1030 (2000).
	A7 ✓	Pawelek, John H. et al., "Tumor-targeted <i>Salmonella</i> as a Novel Anticancer Vector", Cancer Research, vol. 57, 4537-4544 (1997).
	A8 ✓	Potera, Carol, "Harnessing <i>Salmonella</i> 's Positive Powers against Tumors", ASM News, vol. 66, No. 6 (2000).
	A9 ✓	Alexandroff, Anton B. et al., "BCG immunotherapy of bladder cancer: 20 years on", The Lancet, vol. 353, 1689-1694 (May 15, 1999).
	A10 ✓	O'Donnell, Michael A., "The genetic reconstruction of BCG as a new immunotherapeutic tool", Tibtech, vol. 15, 512-517 (December 1997).
	A11 ✓	Paglia, Paola et al., "Keeping the immune system alerted against cancer", Cancer Immunol. Immunother., 46:88-92 (1998).
	A12 ✓	Hunter, Christopher A. et al., "Cutting Edge: Systemic Inhibition of Angiogenesis Underlies Resistance to Tumors During Acute Toxoplasmosis", The Journal of Immunology, 166: 5878-5881 (2001).
	A13 ✓	L. H. Dang et al., "Combination bacteriolytic therapy for the treatment of experimental tumors." Proc. Nat. Acad. Sci. USA, 98, 15155-15160 (2001).


EXAMINER Mishra	DATE CONSIDERED 4-19-05
--------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 05 2002

RECEIVED

X



FORM PTO-1449	SERIAL NO. 10/047,710	CASE NO. 11170/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE January 15th, 2002	GROUP ART UNIT
(use several sheets if necessary)	APPLICANT(S): Das Gupta et al.	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
mf	A14	R. K. Jain and N. S. Forbes, "Can engineered bacteria help control cancer?" Proc. Natl. Acad. Sci. USA, 98, 14748-14750 (2001).
	A15	
	A16	
	A17	

RECEIVED  
APR 05 2002  
TECH CENTER 1600/2900

EXAMINER msm	DATE CONSIDERED 4-19-05
-----------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	SERIAL NO. 10/047,710	CASE NO. 11472/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE January 15 <sup>th</sup> , 2002	GROUP ART UNIT
APPLICANT(S): Das Gupta et al.		

**REFERENCE DESIGNATION U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
MM	B1	U.S. 5789389	Aug 4, 1998	Tarasewicz	Mar 17, 1995

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
MM	B2	A. W. Confer and Janet A. Durham, Am. J. Res., vol. 53, no. 5, pp 646-52 (1992)
	B3	T. Wu et al., Antimicrobial Agents and Chemotherapy, vol. 44, no. 5, pp 1200-08 (May 2000)
	B4	PCT International Application No. PCT/US02/01408 - International Search Report
	B5	M. Kukimoto et al., FEBS Letters, 394, pp 87-90 (1996)
	B6	F. Cutruzzola et al., J. Inorganic Chemistry, 88, pp 353-61 (2002)
	B7	L. M. Murphy et al., J. Mol. Biol., 315, pp 859-71 (2002)
	B8	V Punj & A. M. Chakrabarty, Cellular Microbiology, 5(4), pp 225-31 (2003)
	B9	T Yamada et al., PNAS, Vol. 99, no. 22, pp 14098-103 (2002)
	B10	T. Yamada et al., Infection & Immunity, vol. 70, no. 12, pp 7054-62 (2002)
	B11	M. Goto et al., Mol. Bio., 47(2), pp 549-559 (2003)
	B12	V. Punj et al., Biochemical and Biophysical Research Communications, vol. 312, pp. 109-14 (2003)
	B13	Vasu Punj et al., Oncogene 2003 - Proof copy

EXAMINER <i>Mason</i>	DATE CONSIDERED 4-20-05
--------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449	SERIAL NO. 10/047,710	CASE NO. 11472/3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)	FILING DATE January 15 <sup>th</sup> , 2002	GROUP ART UNIT 1642
APPLICANT(S): Das Gupta et al.		

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
mg	C1	Vasu Punj et al., "Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", Oncogene (2004) 23, 2367-78.

EXAMINER mark	DATE CONSIDERED 4-20-05
------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. 10/047,710	CASE NO. 11472-3
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE January 15, 2002	GROUP ART UNIT 1642
(use several sheets if necessary)		APPLICANT(S): T.K. Das Gupta et al.



EXAMINER INITIAL	OTHER ART - NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.)	
my	D1	Zaborina et al., "Secretion of ATP-utilizing enzymes, nucleoside diphosphate kinase and ATPase, by Mycobacterium bovis BCG: sequestration of ATP from macrophage P2Z receptors?", Molecular Microbiology (1999) 31(5), 1333-1343 X
↓	D2	Anonymous: "Plastocyanin precursor" DATABASE EMBL 'Online!', 1 November 1997, XP002306632 abstract
	D3	Anonymous: "Rusticyanin precursor" DATABASE EMBL 'Online!', 1 March 1992, XP002306633 abstract
	D4	Anonymous: "Pseudoazurin precursor" DATABASE EMBL 'Online!', 1 February 1991, XP002306634 abstract

EXAMINER <i>Musht 2</i>	DATE CONSIDERED 4-20-05
----------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.